<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="29075">Mononucleotide</z:chebi> tracts in the coding regions of the TGFBR2 and BAX genes are commonly mutated in microsatellite instability-high (MSI-high) <z:hpo ids='HP_0003003'>colon cancers</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The receptor TGFBR2 plays an important role in the TGFB1 (transforming growth factor-β, TGF-β) signaling pathway, and BAX plays a key role in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>However, a role of TGFBR2 or BAX <z:chebi fb="0" ids="29075">mononucleotide</z:chebi> mutation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> as a prognostic biomarker remains uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>METHODOLOGY/PRINCIPAL FINDINGS: We utilized a database of 1072 rectal and <z:hpo ids='HP_0003003'>colon cancers</z:hpo> in two prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study) </plain></SENT>
<SENT sid="4" pm="."><plain>Cox proportional hazards model was used to compute mortality hazard ratio (HR), adjusted for clinical, pathological and molecular features including the CpG island methylator phenotype (CIMP), LINE-1 methylation, and KRAS, BRAF and PIK3CA mutations </plain></SENT>
<SENT sid="5" pm="."><plain>MSI-high was observed in 15% (162/1072) of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>TGFBR2 and BAX <z:chebi fb="0" ids="29075">mononucleotide</z:chebi> mutations were detected in 74% (117/159) and 30% (48/158) of MSI-high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In Kaplan-Meier analysis as well as univariate and multivariate Cox regression analyses, compared to microsatellite stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>)/MSI-low cases, MSI-high cases were associated with superior <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific survival [adjusted HR, 0.34; 95% confidence interval (CI), 0.20-0.57] regardless of TGFBR2 or BAX mutation status </plain></SENT>
<SENT sid="8" pm="."><plain>Among MSI-high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, TGFBR2 <z:chebi fb="0" ids="29075">mononucleotide</z:chebi> mutation was associated with CIMP-high independent of other variables [multivariate odds ratio, 3.57; 95% CI, 1.66-7.66; p = 0.0011] </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: TGFBR2 or BAX <z:chebi fb="0" ids="29075">mononucleotide</z:chebi> mutations are not associated with the patient survival outcome in MSI-high <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Our data do not support those mutations as prognostic biomarkers (beyond MSI) in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
</text></document>